Gene markers in brain tumors: What the epileptologist should know

Epilepsia

Volumn 54, Issue SUPPL. 9, 2013, Pages 25-29

  Ostrom, Quinn ^a   Cohen, Mark L ^a,b   Ondracek, Annie ^c   Sloan, Andrew ^a,b   Barnholtz Sloan, Jill ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Biomarker; Brain tumor; Epilepsy; Glioma CpG island DNA methylator phenotype; Isocitrate dehydrogenase 2; Isocitrate dehydrogenase l; Long term epilepsy associated tumors; O6 methylguanine methyltranferase

Indexed keywords

BIOLOGICAL MARKER; DRUG DERIVATIVE; GUANINE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; O (6) METHYLGUANINE; O-(6)-METHYLGUANINE; TUMOR SUPPRESSOR PROTEIN;

BRAIN TUMOR; CPG ISLAND; DNA METHYLATION; EPILEPSY; GENETICS; GLIOMA-CPG ISLAND DNA METHYLATOR PHENOTYPE; HUMAN; LONG-TERM EPILEPSY ASSOCIATED TUMORS; METABOLISM; MUTATION; O6-METHYLGUANINE METHYLTRANFERASE; REVIEW; ANALOGS AND DERIVATIVES; COMPLICATION;

BIOMARKER; BRAIN TUMOR; EPILEPSY; GLIOMA-CPG ISLAND DNA METHYLATOR PHENOTYPE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LONG-TERM EPILEPSY ASSOCIATED TUMORS; O6-METHYLGUANINE METHYLTRANFERASE;

BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPILEPSY; GUANINE; HUMANS; MUTATION; TUMOR SUPPRESSOR PROTEINS;

EID: 84894364640     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12439     Document Type: Article

References (20)

1. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amista P, Morandi L, Spagnolli F, Ermani M. (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 27:1275-1279.
2. Brennan C, Verhaak RGW, Mckenna A, Campos B, Noushmehr H, Salama S, Zheng S, Chakarvarti D, Sanborn JZ, Berman S, Beroukhim R, Bernard B, Wu C-J, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla S, Ciriello G, Lu Y, Yung WK, Zhang W, Kucherlapati R, Perou CM, Gibbs R, Marra M, Gastier-Foster JM, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Laird PW, Haussler D, Gabriel S, Getz G, Chin L, on behalf of the TCGA Research Network. (2013) The somatic genomic landscape of glioblastoma. Cell. 10:462-477.
3. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479.
4. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, Von Deimling A. (2011) Mutation-specificIDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendrogliomalike morphology. Acta Neuropathol 121:241-252.
5. De Groot JF, Sulman EP, Aldape KD. (2011) Multigene sets for clinical application in glioma. J Natl Compr Canc Netw 9:449-456; quiz 457.
6. Engel J Jr. (2011) Biomarkers in epilepsy: introduction. Biomark Med 5:537-544.
7. Everhard S, Tost J, El Abdalaoui H, Criniere E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Thillet J. (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11:348-356.
8. Fischer I, Aldape K. (2010) Molecular tools: biology, prognosis, and therapeutic triage. Neuroimaging Clin N Am 20:273-282.
9. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003.
10. Kaye AH, Laws ER. (2001) Brain tumors: an encyclopedic approach. 2nd ed. Harcourt International, London.
11. Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW. (2011) Omethylguanine- DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS ONE 6:e17156.
12. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522.
13. Olar A, Aldape KD. (2012) Biomarkers classification and therapeutic decision-making for malignant gliomas. Curr Treat Options Oncol 13:417-436.
14. Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, Laframboise WA, Burger PC, Brat DJ, Rosenblum MK, Holmes EJ, Zhou T, Jakacki RI, Children's Oncology G. (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst 27:87-94.
15. Stockhammer F, Misch M, Helms HJ, Lengler U, Prall F, Von Deimling A, Hartmann C. (2012) IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure 21:194-197.
16. Sulman EP, Guerrero M, Aldape K. (2009) Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol 19:142-149.
17. Suri V, Jha P, Sharma MC, Sarkar C. (2011) O6-methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: a review of current status. Neurol India 59:229-235.
18. Thom M, Blumcke I, Aronica E. (2012) Long-term epilepsy-associated tumors. Brain Pathol 22:350-379.
19. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110.
20. Yan H, Parsons DW, Jin G, Mclendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773.